Gasometric gradients between blood obtained from the pulmonary artery wedge and pulmonary artery positions in pulmonary arterial hypertension

Ghaleb Khirfan¹, Mostafa K. Ahmed¹,², Michael D. Faulx³, Wael Dakkak⁴, Raed A. Dweik¹ and Adriano R. Tonelli¹*

Abstract

Introduction: Little is known on the pulmonary gradients of oxyhemoglobin, carboxyhemoglobin and methemoglobin in pulmonary arterial hypertension (PAH). We sought to determine these gradients in group 1 PAH and assess their association with disease severity and survival.

Methods: During right heart catheterization (RHC) we obtained blood from pulmonary artery (PA) and pulmonary artery wedge (PAW) positions and used co-oximetry to test their gasometric differences.

Results: We included a total of 130 patients, 65 had group 1 PAH, 40 had pulmonary hypertension (PH) from groups 2–5 and 25 had no PH during RHC. In all groups, PAW blood had higher pH, carboxyhemoglobin and lactate as well as lower pCO₂ than PA blood. In group 1 PAH (age 58 ± 15 years, 72% females), methemoglobin in the PAW was lower than in the PA blood (0.83% ± 0.43 vs 0.95% ± 0.50, p = 0.03) and was directly associated with the degree of change in pulmonary vascular resistance (R² = 0.35, p = 0.02) during inhaled nitric oxide test. Oxyhemoglobin in PA (HR (95%CI): 0.90 (0.82–0.99), p = 0.04) and PAW (HR (95%CI): 0.91 (0.84–0.98), p = 0.003) blood was associated with adjusted survival in PAH.

Conclusions: Marked differences were observed in the gasometric determinations between PAW and PA blood. The pulmonary gradient of methemoglobin was lower in PAH patients compared to controls and a higher PAW blood methemoglobin was associated with a more pronounced pulmonary vascular response to inhaled nitric oxide. Pulmonary artery and PAW oxyhemoglobin tracked with disease severity and survival in PAH.

Keywords: Blood gas analysis, Methemoglobin, Pulmonary hypertension
oxidation of the hemoglobin iron to a ferric (Fe$^{+++}$) state, a reaction that occurs when oxyhemoglobin reacts with nitric oxide (NO) [11]; therefore levels of metHb may track with levels of NO, a potent vasodilator implicated in the pathogenesis of PAH [12].

Transpulmonary gradients are traditionally measured between pulmonary artery (PA) (mixed venous) and systemic arterial blood (e.g. radial artery) [13–18]; however, arterial blood may be affected by right-to-left shunts from the Thebesian veins and potential metabolic processes between the left heart and the arterial sampling site. An approach to prevent these problems is to obtain blood from the pulmonary artery wedge (PAW) position (Fig. 1), indeed PAW blood has been studied in a variety of diseases [19–21]. Notably, PAW blood can be obtained at the time of right heart catheterization (RHC) without the need for an arterial puncture. In our practice we routinely obtain PA blood (mixed venous) for indirect/direct Fick cardiac output calculation and PAW blood to support an adequate PAW measurement [22]. Given that there is limited information on the pulmonary gradients of certain gases in PAH, we used co-oximetry to test the differences between blood obtained at the PA and PAW positions. We hypothesize that patients with PAH (group 1) have derangements in COHb and metHb as a result of defects in the NO pathway. We further hypothesize that COHb and metHb gradients may not only provide an insight on the metabolic processes that occur in the lungs of PAH patients but may be associated with disease severity, inhaled NO response and survival.

**Materials and methods**

**Subjects and study design**

This cross-sectional study was approved by the Cleveland Clinic institutional review board (study number: 06–245 and 14–1069). Written informed consent was waived given the retrospective nature of the study. We included consecutive patients who underwent RHC either to a) diagnose pulmonary hypertension (PH) or b) manage patients with prior diagnosis of PH. Right heart catheterizations were performed between December 2012 and April 2015.

We carefully assessed each patient to determine the etiology of PH based on the Fifth World Symposium classification [23]. Group 1 PH includes the idiopathic and heritable forms, PH associated with drugs, toxins, connective tissue and congenital heart diseases, portal hypertension, HIV infection and schistosomiasis. Group 2, 3, 4 and 5 includes PH due to left heart disease, lung disease/hypoxia, chronic thromboembolic disease and multifactorial mechanisms, respectively. For the purpose of this study, patients were divided into three groups: a) patients with PAH (PH group 1), 2) patients with PH groups 2–5, and 3) age- and gender-matched subjects without evidence of resting PH on RHC (mPAP < 25 mmHg). Patients without PH underwent RHC due to elevated right ventricular systolic pressure on echocardiography. Patients were excluded ($n$ = 50) if the PAW blood could not be obtained during RHC or if it showed an SO$_2$ < 90%, suggestive of an inadequate balloon wedging with leakage of deoxygenated blood from the proximal (before the balloon) to the distal (after the balloon) aspect of the PA catheter.

**Right heart catheterization**

Subjects underwent RHC in the outpatient setting by a single operator (A.R.T.). All RHC were done under local anesthesia using 5 mL of 2% lidocaine. We continued or started oxygen (O$_2$) supplementation in patients in whom the resting pulse oxygen saturation (SpO$_2$) was < 90%. We maintained the same O$_2$ flow during all the study measurements. In the supine position and with the transducer located in the mid-thoracic line (4th intercostal space), we measured the right atrial (RA) pressure, mean PAP and PAWP at end-expiration. We determined cardiac output (CO) by thermodilution. We calculated the cardiac index (CO / body surface area), the transpulmonary pressure gradient (TPG: mean PAP - PAWP), diastolic pulmonary gradient (DPG: diastolic PAP – PAWP) and PVR (TPG / CO). When appropriate, we performed a pulmonary vasodilator challenge using inhaled NO at 40 ppm for 5 min [24].

**Laboratory determinations**

Pulmonary artery and PAW blood were obtained immediately after fluoroscopic site confirmation and obtaining an adequate waveform. The tip of the pulmonary artery catheter was located in West zone 3 [25]. Ten mL of blood
were discarded from each site before a sample was collected in a blood gas syringe. Blood gas samples were immediately analyzed using the ABL 800 Flex analyzer (Radiometer, Copenhagen, Denmark) which uses co-oximetry and provide determinations of COHb, metHb, Hb and lactate.

Other measurements
We collected data regarding demographics, use of PAH-specific medications and smoking status (current smoker was defined as a person who smoked tobacco in the last 30 days). We determined the severity of PH by using the New York Heart Association (NYHA) functional class, plasma N-terminal pro-B type natriuretic peptide (NT-proBNP), distance walked in the six-minute walk test (6MWD), RV size and function on echocardiography and hemodynamic determinations during RHC. Right ventricular function was determined both subjectively by visual inspection and objectively by the tricuspid annular plane systolic excursion (TAPSE) [26]. We also recorded the diffusion lung capacity for carbon monoxide corrected for Hb (DLCOc) [27].

Statistical analysis
Continuous data are presented as mean ± standard deviation (SD) or median (interquartile range (IQR)) as appropriate. Categorical data are summarized as discrete values and percentages (n (%)). Continuous and categorical variables were compared across the groups using analysis of variance (ANOVA) and Chi-square, respectively. Paired data were contrasted with paired t test or Friedman test as appropriate. Associations were tested using the Pearson correlation test. Survival analysis was performed with Cox proportional hazards model adjusted by age, gender and other pre-specified variables. The starting point for the survival analyses was the date of the gasometric determinations. Patients were censored at the time of lung transplantation and followed until death or end of the study in January 2018. Cox proportional hazards model results are expressed as hazard ratios (HR) with the corresponding 95% confidence intervals (CI). All p values are two-tailed and a value of < 0.05 was considered significant. The statistical analyses were performed using the statistical packages IBM SPSS, version 20 (IBM; Armonk, New York) and MedCalc, version 14.12.0 (Ostend, Belgium).

Results
Baseline characteristics
We included a total of 130 patients, of whom 65 had group 1 PAH, 40 had PH from groups 2–5 and 25 had no PH during RHC. Of the patients with PAH, 38 (58%) had idiopathic or heritable PAH, 17 (26%) had PAH associated with connective tissue diseases, 5 (8%) had porto-pulmonary hypertension and 5 (8%) had PAH due to other etiologies. Patients with non-group 1 PH belonged to PH groups 2 (n = 20, 50%), 3 (n = 10, 25%), 4 (n = 5, 12.5%) and 5 (n = 5, 12.5%). All patients without PH (n = 25, 19%) had an elevated RVSP (≥ 40 mmHg) and associated diseases such as scleroderma, cirrhosis, interstitial lung disease, obstructive sleep apnea or suggestion of left ventricular diastolic dysfunction by echocardiogram.

Of the patients with PAH, 18 (28%), 15 (23%), 20 (31%) and 12 (19%) were on none, 1, 2, and 3 PAH-specific therapies, respectively. These PAH-specific therapies were phosphodiesterase-5 inhibitors (n = 39, 60%), endothelin receptor antagonists (n = 25, 39%), soluble guanylate cyclase stimulator (n = 1, 2%), and prostacyclin analogues (n = 26, 40%). Baseline characteristics of the three groups of patients are shown in Table 1.

Comparison of PAW and PA blood in patients with group 1 PAH
We observed significant differences between the PAW and PA blood in PAH patients. PAW blood had higher pH, COHb and lactate as well as lower pCO₂, bicarbonate and metHb when compared to the PA blood (Table 2).

Comparison of PAW and PA blood gradients among study groups
A comparison among the three study groups (group 1 PAH, non-group 1 PH and no PH) showed that the pH increase in the PAW compared to the PA blood was more pronounced in group 1 PAH patients (Table 3). We also noted that the metHb was lower in the PAW relative to PA blood in patients with PH (group 1 PAH and non-group 1 PH) compared to individuals without PH (Table 3). In fact, in individuals without PH, metHb was higher in the PAW than in the PA blood (mean (95% CI) difference: 0.12 (+ 0.01, + 0.23), p = 0.04).

Association between blood gases, gradients and disease severity in group 1 PAH patients
The gradient of O₂Hb between PAW and PA was directly associated with RA pressure (R: 0.34, p = 0.006), PVR (R: 0.35, p = 0.006) and NT-proBNP (R: 0.36, p = 0.03) and inversely associated with CI (R: -0.43, p < 0.001) and TAPSE (R: -0.32, p = 0.013). Other gasometric gradients were not significantly associated with markers of disease severity.

Response to inhaled NO challenge and gasometric determinations in group 1 PAH patients
In group 1 PAH patients: the PVR decreased a mean of 16.3% ± 16.9% (n = 45). The percentage drop in PVR was inversely associated with Hb (R = -0.34, p = 0.02) and directly associated with metHb (R = 0.35, p = 0.02) and O₂Hb (R = 0.321, p = 0.03) in the PAW blood.
Table 1 Baseline patient characteristics

| Variable                        | Group 1 pulmonary arterial hypertension | Groups 2–5 pulmonary hypertension | Control group | P (ANOVA / Chi square) |
|---------------------------------|----------------------------------------|-----------------------------------|---------------|------------------------|
| n (%)                           | 65 (50.0)                              | 40 (30.8)                         | 25 (19.2)     |                        |
| Age (years)                     | 58 ± 15                                 | 59 ± 20                           | 54 ± 20       | 0.52                   |
| Female gender, n (%)            | 47 (72)                                | 40 (55)                           | 25 (60)       | 0.17                   |
| NYHA functional class, n (%)    |                                        |                                   |               |                        |
| I                               | 5 (8)                                  | 4 (10)                            | 6 (24)        | 0.14                   |
| II                              | 26 (40)                                | 10 (25)                           | 9 (36)        |                        |
| III                             | 31 (48)                                | 22 (55)                           | 10 (40)       |                        |
| IV                              | 3 (5)                                  | 4 (10)                            | 0 (0)         |                        |
| Supplemental O₂, n (%)          | 29 (45)                                | 21 (53)                           | 6 (24)        | 0.07                   |
| FI O₂ in patients on supplemental O₂ (%) | 42 ± 22                               | 35 ± 16                           | 29 ± 3        | 0.21                   |
| NT-proBNP (pg/mL)               | 2084 ± 3247                            | 2087 ± 2737                       | 180 ± 153     | 0.06                   |
| 6MWD (m)                        | 310 ± 129                              | 317 ± 106                         | 343 ± 130     | 0.61                   |
| DLCOc (% predicted)             | 54 ± 15                                | 51 ± 28                           | 60 ± 26       | 0.43                   |
| Echocardiography                |                                        |                                   |               |                        |
| TAPSE (cm)                      | 1.90 ± 0.62                            | 1.81 ± 0.62                       | 2.68 ± 0.80   | 0.45                   |
| RVSP (mm Hg)                    | 73 ± 26                                | 63 ± 22                           | 50 ± 18       | 0.001                  |
| RHC                             |                                        |                                   |               |                        |
| RA pressure (mmHg)              | 8 ± 6                                  | 9 ± 5                             | 4 ± 3         | 0.001                  |
| mPAP (mmHg)                     | 42 ± 14                                | 37 ± 10                           | 17 ± 5        | < 0.001                |
| PAWP (mmHg)                     | 10 ± 5                                 | 15 ± 6                            | 8 ± 3         | < 0.001                |
| TPG (mmHg)                      | 32 ± 13                                | 23 ± 10                           | 9 ± 3         | < 0.001                |
| CI (L/min/m²)                   | 3.0 ± 0.9                              | 2.7 ± 0.8                         | 3.2 ± 0.7     | 0.06                   |
| PVR (Wood units)               | 6.7 ± 4.2                              | 5.0 ± 3.5                         | 1.5 ± 0.8     | < 0.001                |
| Gasometric determinations (PA)  |                                        |                                   |               |                        |
| pH                              | 7.41 ± 0.03                            | 7.39 ± 0.04                       | 7.40 ± 0.03   | 0.06                   |
| pCO₂ (mmHg)                     | 41.8 ± 5.7                             | 47.7 ± 8.5                        | 44.6 ± 4.6    | < 0.001                |
| SO₂ (%)                         | 68.1 ± 7.6                             | 66.6 ± 9.7                        | 72.4 ± 5.9    | 0.02                   |
| COHb (%)                        | 1.6 ± 1.1                              | 1.6 ± 0.9                         | 1.4 ± 1.0     | 0.68                   |
| metHb (%)                       | 1.0 ± 0.5                              | 0.9 ± 0.4                         | 0.8 ± 0.4     | 0.22                   |
| Lactic acid (mmol/L)            | 0.8 ± 0.4                              | 1.1 ± 0.5                         | 1.0 ± 0.4     | 0.008                  |
| Gasometric determinations (PAW) |                                        |                                   |               |                        |
| pH                              | 7.54 ± 0.08                            | 7.49 ± 0.10                       | 7.49 ± 0.08   | 0.02                   |
| pCO₂ (mmHg)                     | 27.1 ± 8.2                             | 34.0 ± 10.6                       | 32.3 ± 7.4    | 0.001                  |
| SO₂ (%)                         | 93.6 ± 5.4                             | 92.0 ± 7.0                        | 93.4 ± 3.6    | 0.38                   |
| COHb (%)                        | 1.8 ± 1.2                              | 1.7 ± 1.1                         | 1.6 ± 1.0     | 0.88                   |
| metHb (%)                       | 0.8 ± 0.4                              | 0.8 ± 0.4                         | 0.9 ± 0.4     | 0.84                   |
| Lactic acid (mmol/L)            | 0.9 ± 0.4                              | 1.2 ± 0.6                         | 1.1 ± 0.5     | 0.04                   |

Definition of Abbreviations: COHb: carboxyhemoglobin, CI: cardiac index, DLCOc: diffusion lung capacity for carbon monoxide corrected for hemoglobin, FI O₂: fraction of inspired oxygen, metHb: methemoglobin, mPAP: mean pulmonary artery pressure, NT-proBNP: N-terminal pro-B type natriuretic peptide, NYHA: New York Heart Association, PA: pulmonary artery, PAWP: pulmonary artery wedge, pCO₂: partial pressure of carbon dioxide, PVR: pulmonary vascular resistance, RA: right atrial, RHC: right heart catheterization, RVSP: right ventricular systolic pressure, SO₂: oxygen saturation, TAPSE: tricuspid annular plane systolic excursion, TPG: transpulmonary pressure gradient, 6MWD: distance walked in six-minute walk test

Data are expressed as mean ± SD or n (%)
Relationship between blood determinations, gradients and survival in PH patients

The median (IQR) follow-up for patients with type 1 PAH was 41 (22–51) months, with a 2-year survival of 78%. When adjusted for age and gender, variables associated with mortality in group 1 PAH included: PA $O_2$Hb (HR (95%CI): 0.87 (0.81–0.94), p = 0.001) and PAW $O_2$Hb (HR (95%CI): 0.93 (0.87–0.98), p = 0.01). Pulmonary artery $O_2$Hb was associated with mortality even when adjusted by supplemental oxygen therapy (HR (95%CI): 0.89 (0.82–0.96), p = 0.003) and adding PVR, 6MWD and number of PAH-specific therapies (HR (95%CI):0.90 (0.82–0.99), p = 0.04). Pulmonary artery wedge $O_2$Hb continued to be a significant predictor when adjusted by supplemental oxygen therapy (HR (95%CI): 0.89 (0.83–0.96), p = 0.001), PA $O_2$Hb (HR (95%CI): 0.88 (0.82–0.95), p = 0.001), and adding PVR, 6MWD and number of PAH-specific therapies (HR

Table 2 Comparison of pulmonary artery wedge and mixed venous blood in pulmonary arterial hypertension patients (n = 63)

| Variable       | Pulmonary artery wedge blood | Mixed venous blood | Mean difference | 95% CI of the difference | P (paired T test) |
|----------------|------------------------------|--------------------|-----------------|--------------------------|------------------|
| pH             | 7.53 ± 0.08                  | 7.40 ± 0.03        | 0.13            | 0.11 to 0.15              | <0.001           |
| pCO₂ (mmHg)    | 27.1 ± 8.2                   | 41.9 ± 5.7         | −14.80          | −16.42 to −13.10          | <0.001           |
| pO₂ (mmHg)     | 104.4 ± 53.5                 | 39.6 ± 4.7         | 64.85           | 51.40 to 78.30            | <0.001           |
| pO₂ a (mmHg)   | 82.5 ± 24.9                  | 40.1 ± 4.8         | 42.48           | 38.01 to 50.96            | <0.001           |
| HCO₃⁻ (mmol/L) | 22.3 ± 4.0                   | 25.7 ± 3.3         | −3.39           | −3.83 to −2.96            | <0.001           |
| O₂Hb (%)       | 93.6 ± 5.4                   | 68.3 ± 7.3         | 25.28           | 22.95 to 27.61            | <0.001           |
| O₂Hb a (%)     | 92.7 ± 6.5                   | 70.5 ± 6.3         | 22.20           | 19.11 to 25.28            | <0.001           |
| COHb (%)       | 1.76 ± 1.18                  | 1.59 ± 1.1         | 0.16            | 0.06 to 0.26              | 0.002            |
| COHb b (%)     | 1.52 ± 0.79                  | 1.33 ± 0.61        | 0.16            | 0.07 to 0.24              | <0.001           |
| metHb (%)      | 0.83 ± 0.43                  | 0.95 ± 0.50        | −0.12           | −0.23 to −0.01            | 0.03             |
| Hb (g/dL)      | 12.7 ± 2.4                   | 12.8 ± 2.3         | −0.11           | −0.29 to +0.07            | 0.24             |
| Lactate (mmol/L) | 0.94 ± 0.35                 | 0.82 ± 0.36        | 0.12            | 0.08 to 0.15              | <0.001           |

Definition of Abbreviations: CI: confidence interval, COHb: carboxyhemoglobin, Hb: hemoglobin, HCO₃⁻: bicarbonate, metHb: methemoglobin, O₂Hb: oxyhemoglobin, pCO₂: partial pressure of carbon dioxide, pO₂: partial pressure of oxygen

Data are expressed as mean ± SD

aPatients not on Oxygen supplementation (n = 36)
b nonsmokers patients only (n = 60)

Table 3 Differences between pulmonary artery wedge and mixed venous blood in the three groups of patients

| Variable       | Group 1 pulmonary arterial hypertension | Groups 2–5 pulmonary hypertension | Control group | P (ANOVA / Chi square) |
|----------------|----------------------------------------|-----------------------------------|---------------|------------------------|
| n (%)          | 65 (50.0)                              | 40 (30.8)                         | 25 (19.2)     |                        |
| pH             | 0.13 ± 0.07                            | 0.10 ± 0.09                       | 0.09 ± 0.06   | 0.05                   |
| pCO₂ (mmHg)    | −14.7 ± 6.6                            | −14.2 ± 8.0                       | −12 ± 6.0     | 0.34                   |
| pO₂ (mmHg)     | 64.9 ± 53.4                            | 58.0 ± 47.4                       | 42.7 ± 27.0   | 0.14                   |
| pO₂ a (mmHg)   | 42.5 ± 24.7                            | 36.4 ± 21.3                       | 40.9 ± 26.5   | 0.70                   |
| HCO₃⁻ (mmol/L) | −3.4 ± 1.7                             | −3.0 ± 1.4                        | −2.9 ± 1.3    | 0.33                   |
| O₂Hb (%)       | 25.3 ± 9.3                             | 23.7 ± 9.6                        | 21.0 ± 6.3    | 0.12                   |
| O₂Hb a (%)     | 22.2 ± 9.0                             | 25.1 ± 6.7                        | 21.9 ± 6.1    | 0.39                   |
| COHb (%)       | 0.16 ± 0.40                            | 0.09 ± 0.41                       | 0.21 ± 0.53   | 0.55                   |
| COHb b (%)     | 0.17 ± 0.41                            | 0.09 ± 0.42                       | 0.22 ± 0.56   | 0.55                   |
| metHb (%)      | −0.12 ± 0.42                           | −0.11 ± 0.43                      | 0.12 ± 0.27   | 0.04                   |
| Hb (g/dL)      | −0.11 ± 0.74                           | −0.19 ± 0.50                      | 0.10 ± 0.61   | 0.20                   |
| Lactate (mmol/L)| 0.12 ± 0.13                            | 0.10 ± 0.14                       | 0.06 ± 0.08   | 0.12                   |

Definition of Abbreviations: CI: confidence interval, COHb: carboxyhemoglobin, Hb: hemoglobin, HCO₃⁻: bicarbonate, metHb: methemoglobin, O₂Hb: oxyhemoglobin, pCO₂: partial pressure of carbon dioxide, pO₂: partial pressure of oxygen

Data are expressed as mean ± SD

aPatients not on Oxygen supplementation

b nonsmokers patients only
Carboxyhemoglobin is produced endogenously during the oxidation of heme compounds by heme oxygenase [35]. The carbon monoxide released from this catabolic reaction has vasodilatory [36], anti-inflammatory [37] and anti-proliferative properties [4]. Hypoxia transiently increases expression of heme oxygenase [38, 39]. The increased expression of heme oxygenase prevented the development of PH induced by hypoxia [38, 39] a mechanism that may involve the anti-proliferative action of carbon monoxide [39]. In the present study, we found that COHb is higher in the PAW compared to PA blood in all groups of patients, suggesting pulmonary production and systemic metabolism of carbon monoxide. A finding consistent with prior studies which showed positive arteriovenous COHb difference, with higher COHb in arterial compared to venous blood [8, 34, 40].

Analysis of survival in group 1 PAH patients showed that PA and PAW O2Hb adjusted by age, gender, use of supplemental oxygen, PVR and 6MWD are independent predictors of long-term survival. The association between PA O2Hb and survival was expected given previous research [41, 42]. The association between PAW blood O2Hb and survival is novel and consistent with our prior study showing that hypoxemia (determined by pulse oximetry) in patients with idiopathic and heritable PAH is associated with worse survival [43].

Our study has limitations: a) retrospective analysis, b) even though the gasometric differences of metHb are small and might not be clinically significant, they provide an insight on the complex physiological processes involving nitric oxide and c) although patients had a detailed smoking history, surreptitious smoking or other environmental exposure that increased carbon monoxide could not be ruled out. Smoking may affect the pulmonary endothelium, leading to pulmonary vascular remodeling and PH, even in the absence of hypoxemia and destructive emphysematous lung disease [44–48]. Despite these limitations, our study is the first to assess the gasometric gradients between PAW and PA blood in patients with PAH.

Conclusions
Pulmonary artery wedge blood samples had higher pH and lower pCO2 than PA, suggesting that PAW blood was exposed to alveolar gas for a longer period of time. Methylene levels were lower in the PAW than PA blood in patients with PAH and a higher PAW metHb was associated with a more pronounced pulmonary vascular response to inhaled NO. Pulmonary artery and PAW O2Hb tracked with disease severity and survival in PAH patients.
This study was approved by the Cleveland Clinic institutional review board.

Ethics approval and consent to participate

This study was approved by the Cleveland Clinic institutional review board (study number: 06–104 and 14–1069). Written informed consent was waived given the retrospective nature of the study.

Competing interests

Ghaleb Khirfan MD: The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

Mostafa K. Ahmed MD: The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

Michael D. Faul MD: The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

Wael Dalkak MD: The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

Raed A. Dweik MD: The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

Adriano R. Tonelli MD: The author has no significant conflicts of interest with any companies or organization whose products or services may be discussed in this article.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue A-90, Cleveland, OH 44195, USA. 2Department of Chest Diseases, Faculty of Medicine, Assiut University, Assiut, Egypt. 3Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. 4Department of Internal Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.

References

1. Tonelli AR, Arelli V, Minai OA, Newman J, Bair N, Heresi GA, Dweik RA. Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188:365–9.
2. Hooper MM, Bogaard HJ, Corduffe R, Frantz R, Khanna D, Kuzyma M, Langleben D, Manes A, Satoth T, Torres F, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–50.
3. Pabalan MJ, Nayak SP, Ryan RM, Kumar VH, Lakshminrusimha S. Methemoglobin to cumulative nitric oxide ratio and response to inhaled nitric oxide in PHHH. J Perinatol. 2009;29:698–701.
4. Morita T, Perella MA, Lee ME, Kourembanas S. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc Natl Acad Sci U S A. 1995;92:1475–9.
5. Morita T, Matsuals SA, Koike H, Liu Y, Kourembanas S. Carbon monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J Biol Chem. 1997;272:32804–9.
6. Kourembanas S. Hypoxia and carbon monoxide in the vasculature. Antioxid Redox Signal. 2002;4:291–9.
7. Montellano PR. The mechanism of heme oxygenase. Curr Opin Chem Biol. 2000;4:221–7.
8. Meyer J, Prien T, Van Aken H, Bone HG, Waurick R, Thelmeieger G, Booie M. Arterio-venous carboxyhemoglobin difference suggests carbon monoxide production by human lungs. Biochem Biophys Res Commun. 1982;442:230–2.
9. Schane M, Bone HG, Van Aken H, Meyer J. Increased carbon monoxide in exhaled air of critically ill patients. Biochem Biophys Res Commun. 2000;260:423–6.
10. Dubuis E, Gautier M, Melin A, Rebocho M, Girardin C, Bonnet P, Vanders C. Chronic carbon monoxide enhanced Ibx-sensitive currents in rat resistance pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2002;283L120–9.
11. Privat C, Lantoine F, Bedioui F, Millanvoye van Brussel E, Devynck J, Devynck MA. Nitric oxide production by endothelial cells: comparison of three methods of quantification. Life Sci. 1997;61:1193–202.
12. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;332:214–9.
13. Johnson ML, Emhoff CA, Horning MA, Brooks GA, Transluminal pulmonary artery. J Am Coll Cardiol. 1982;10:636–41.
14. De Backer D, Creteur J, Zhang H, Norrenberg M, Vincent JL. Lactate production by the lungs in acute lung injury. Am J Respir Crit Care Med. 1997;156:1099–104.
15. Bendjeldj K, Treggiari MM, Romand JA. Transluminal pulmonary gradient after hypothemic cardiopulmonary bypass. Intensive Care Med. 2004;30:817–21.
16. Wang TL, Hsu KL, Chang FT, Tseng CD, Tseng YZ. Anaerobic metabolism in patients undergoing intra-aortic balloon counterpulsation for cardiogenic shock. J Formos Med Assoc. 1996;95:379–85.
17. Inoue T, Sakai Y, Morooka S, Hayashi T, Takabatake Y, Yamaguchi H, Kartabatake Y. Venoarterial carbon dioxide tension gradient in acute heart failure. Cardiology. 1993;82:383–7.
18. Harris P, Bayley T, Barman M, Fitzgerald MG, Glaster J, Harris EA, Donald KW. Lactate, pyruvate, glucose, and free fatty acid in mixed venous and arterial blood. J Appl Physiol. 1963;18:933–6.
19. Williams WH Jr, Olsen GN, Allen WG, Yergin BM. Use of blood gas values to estimate the source of blood withdrawn from a wedged flow-directed catheter in critically ill patients. J Crit Care Med. 1982;10:636–40.
20. Brewster H, McIlroy MB. Blood gas tensions and pH of pulmonary arterial blood in patients with pulmonary arterial hypertension. J Appl Physiol. 1973;34:413–6.
21. Safian RD, Come SE, Kadim M, Lorell BH. Use of pulmonary capillary wedge inflation volume on pulmonary artery occlusion pressure in patients with and without pulmonary hypertension. Chest. 2011;139:115–21.
22. Simonneau G, Gatzeulos MA, Adata J, Celemajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34–41.
23. Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med. 2010;104:481–96.
25. West JB, Dollery CT. Distribution of blood flow and the pressure-flow relations of the whole lung. J Appl Physiol. 1965;20:175–83.

26. Ahmed M, Dweik RA, Tonelli AR. What is the best approach to a high systolic pulmonary artery pressure on echocardiography? Cleve Clin J Med. 2016;83:256–60.

27. MacIntyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–35.

28. Hoepier M, Pletz M, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2007;29:944–50.

29. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–23.

30. Douzinas EE, Tsidemiadou PD, Pitaridis MT, Andrianakis I, Bobota-Chloraki A, Katsouyanni K, Sfyras D, Malagari K, Roussos C. The regional production of cytokines and lactate in sepsis-related multiple organ failure. Am J Respir Crit Care Med. 1997;155:53–9.

31. Brown SD, Clark C, Gutierrez G. Pulmonary lactate release in patients with sepsis and the adult respiratory distress syndrome. J Crit Care. 1996;11:2–8.

32. Zapol WM, Rimar S, Gillis N, Marletta M, Bosken CH. Nitric oxide and the lung. Am J Respir Crit Care Med. 1994;149:1375–80.

33. Gow AJ, Luchsinger BP, Pawloski JR, Singel DJ, Stamler JS. The oxyhemoglobin reaction of nitric oxide. Proc Natl Acad Sci U S A. 1999;96:9027–32.

34. Naples R, Laskowski D, McCarthy K, Mathieu E, Cornhari SA, Erzuron SC. Carboxyhemoglobin and methemoglobin in asthma. Lung. 2015;193:183–7.

35. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem. 1969;244:388–94.

36. Furchgott RF, Jothianandan D. Endothelium-dependent and -independent vasoilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood Vessels. 1991;28:52–61.

37. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis R, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med. 2000;6:422–8.

38. Liang OD, Mitsialis SA, Chang MS, Vergadi E, Lee C, Adam M, Fernandez-Gonzalez A, Liu X, Boveja R, Kourembanas S. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells. 2011;29:107.

39. Christou H, Motta T, Hsieh CM, Kolkie H, Arnonac B, Perrella MA, Kourembanas S. Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat. Circ Res. 2000;86:1224–9.

40. Yasuda H, Sasaki T, Yamaya M, Elhara S, Maruyama M, Kanda A, Sasaki H. Increased arteriovenous carboxyhemoglobin differences in patients with inflammatory pulmonary diseases. Chest. 2004;125:2160–8.

41. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, Guerrero ML. Survival in primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106:319–24.

42. Khirfan G, Naal T, Abuhalimeh B, Newman J, Heresi GA, Dweik RA, Tonelli AR. Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS One. 2018;13:e0191869.

43. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax. 2005;60:605–9.

44. Wright JL, Churg A. Effect of long-term cigarette smoke exposure on pulmonary vascular structure and function in the Guinea pig. Exp Lung Res. 1991;17:997–1009.

45. Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD. Am J Respir Crit Care Med. 2008;178:988–94.

46. Ferrer E, Peinado VI, Diez M, Carrasco JL, Musi MM, Martinez A, Rodriguez-Rosin R, Barbera JA. Effects of cigarette smoke on endothelial function of pulmonary arteries in the Guinea pig. Respir Physiol. 2009;70:67.

47. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21:992–905.